Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment
Source: Daniel Carlson for Streetwise Reports  (9/14/18)
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. More >

Canadian Biopharma to Outlicense Pain Drug to South Korean Firm
Source: Streetwise Reports  (9/12/18)
An Echelon Wealth Partners report discussed the deal terms.
More >

Biopharma's Positive FDA Meeting Outlines Path Forward for Trial
Source: Streetwise Reports  (9/11/18)
A ROTH Capital Partners note explained the outcome of the tête-a-tête and its implications.

More >

Final Approval of Biopharma's Lead Candidate Both Likely and Imminent
Source: Streetwise Reports  (9/5/18)
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. More >

Drug Company Receives $5 Million Milestone Payment
Source: Streetwise Reports  (8/31/18)
Company entitled to receive quarterly earn-out payments from patent agreement. More >

Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment
Source: Streetwise Reports  (8/29/18)
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. More >

Oncology-Focused Biotech Receives Orphan Status for AML Drug
Source: Streetwise Reports  (8/29/18)
An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates. More >

Investor Opportunity Arises from Biopharma's Share Price Weakness on Competitor News
Source: Streetwise Reports  (8/29/18)
An analyst discussed the implications to this firm of a competitive product's advancement.
More >

As Nitric Oxide Comes Off Patent, Lower-Cost Options for Life Saving Drug Becoming Possible
Source: Streetwise Reports  (8/22/18)
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available. More >

Coverage Initiated on Developer of Brachytherapy Products for Cancer Treatment
Source: Streetwise Reports  (8/22/18)
H.C. Wainwright & Co. analyst Jason Kolbert provided the rationale for investment in this company. More >

Biotech Marks Progress on Programs for Cancer, Infectious Diseases
Source: Streetwise Reports  (8/15/18)
This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst. More >

Biopharma Signs Multimillion-Dollar Deal for Key Products in China
Source: Streetwise Reports  (8/8/18)
An H.C. Wainwright & Co. report reviewed the arrangement. More >

U.S. Medical Device Firm Pursues ISO 13485 Certification
Source: Streetwise Reports  (8/1/18)
With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system. More >

Cash Stream from Licensing Deal to Help Biopharma Advance Lead Drug
Source: Streetwise Reports  (8/1/18)
A Laidlaw & Co. report discussed this firm's revenue and near-term, clinical catalysts. More >

Biotech Releases White Paper on Alzheimer's Disease Candidate
Source: Streetwise Reports  (8/1/18)
A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate. More >

Interim Readout for Pharma Trial 'Delivers Home Run'
Source: Streetwise Reports  (7/31/18)
An H.C. Wainwright & Co. report discussed the implications of data indicating "overwhelming evidence of efficacy" for this company's nonantibiotic anti-infective for treatment of catheter-related bloodstream infections. More >

Biopharma Releases New Antibiotic in the US for Complicated UTIs
Source: Streetwise Reports  (7/24/18)
A LifeSci Capital report reviewed why uptake of a drug that targets complicated urinary tract infections could be significant and swift. More >

Australian Regenerative Medicine Firm 'Lands a Great Partner in China'
Source: Streetwise Reports  (7/22/18)
A Maxim Group report reviewed the deal between the two companies. More >

Cannabis Firm Targets Sexual Health and Wellness
Source: Ron Struthers for Streetwise Reports  (7/17/18)
California, with nearly 40 million residents, offers a cannabis market as large as the whole of Canada, says Ron Struthers, editor of Struthers Resource Stock Report. He believes that companies that have a road into California will gain early traction, and he profiles one such firm. More >

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC
Source: Streetwise Reports  (7/11/18)
A poster outlining data from this company's lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer's disease, will be presented at the Alzheimer's Association International Conference (AAIC). More >

Study Shows Biopharma's Lead Drug Mediates T Cell Tumor Infiltration
Source: Streetwise Reports  (7/10/18)
An Echelon Wealth Partners report discussed this firm's stock performance and how a recent clinical trial update impacted it. More >

Coverage Initiated on 'True Original' Using RNAi to Enhance Cancer Immunotherapy
Source: Streetwise Reports  (7/10/18)
An H.C. Wainwright & Co. report outlined the thesis for investing in this emerging biotech. More >

EpiPen Rival Lands Major Partner
Source: Streetwise Reports  (7/3/18)
An H.C. Wainwright & Co. report explains the deal, which concerns a new single-dose epinephrine injection for severe allergic reactions. More >

Target Price Increased on Biotech After Q2/18 Revenue Record, Beat
Source: Streetwise Reports  (7/3/18)
A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies. More >

Coverage Initiated on Biopharma with 'Opioid Sparing Solution for Post-Op Pain'
Source: Streetwise Reports  (6/27/18)
An H.C. Wainwright & Co. report highlighted the advantages, status and potential of this lead asset. More >